Evidence map›Paper›PMID 42325645›Full record

Trial reportOpen forum infectious diseases2026

RIMOXCLAMIN's Therapeutic Impact in a Larger Brazilian Hansen's Disease Population.

Marco Andrey Cipriani Frade, Gustavo Sartori Albertino, Natália Aparecida de Paula, Fabiana Aparecida Correa Cinto, Fernanda Cruz Perecin, Andrezza Westin, Mariane de Moraes Monteiro, Wilson Marques Junior, Helena Barbosa Lugão, Filipe Rocha Lima

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marco Andrey Cipriani FradeDivision of Dermatology, Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.ORCID https://orcid.org/0000-0003-2700-5971
Gustavo Sartori AlbertinoNational Referral Center for Sanitary Dermatology and Hansen's Disease, Division of Dermatology, Department of Internal Medicine, Clinical Hospital of the Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.ORCID https://orcid.org/0000-0003-0728-7828
Natália Aparecida de PaulaDivision of Dermatology, Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.ORCID https://orcid.org/0000-0002-3744-8947
Fabiana Aparecida Correa CintoPharmaceutical Assistance Division-Specialized Unit for Treatment of Infectious Diseases of Clinical Hospital, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.ORCID https://orcid.org/0000-0003-0091-3451
Fernanda Cruz PerecinDivision of Dermatology, Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Andrezza WestinDivision of Dermatology, Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.ORCID https://orcid.org/0000-0003-4256-208X
Mariane de Moraes MonteiroDivision of Dermatology, Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.ORCID https://orcid.org/0009-0005-2891-0027
Wilson Marques JuniorNational Referral Center for Sanitary Dermatology and Hansen's Disease, Division of Dermatology, Department of Internal Medicine, Clinical Hospital of the Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Helena Barbosa LugãoNational Referral Center for Sanitary Dermatology and Hansen's Disease, Division of Dermatology, Department of Internal Medicine, Clinical Hospital of the Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.ORCID https://orcid.org/0000-0003-1623-7443
Filipe Rocha LimaNational Referral Center for Sanitary Dermatology and Hansen's Disease, Division of Dermatology, Department of Internal Medicine, Clinical Hospital of the Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.ORCID https://orcid.org/0000-0001-7629-4963

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: RIMOXCLAMIN, a new antibiotic regimen for Hansen's disease (HD), combines rifampicin, moxifloxacin, clarithromycin, and minocycline; the WHO-MDT combines rifampicin, dapsone, and clofazimine. To overcome limitations of WHO-MDT, we evaluated both regimens in a 2-arm cohort of multibacillary patients. Methods: Two-arm observational cohort included 162 newly diagnosed multibacillary cases (103 RIMOXCLAMIN and 59 WHO-MDT) evaluated between 2015 and 2025. Patients were assessed at least quarterly (baseline and months 3, 6, and 12) for neurological and cutaneous findings, adverse events, tactile sensitivity, and physical disability grade (PDG). Results: Neurological symptoms were frequent regardless of lesion count (≤5 vs > 5; Conclusions: RIMOXCLAMIN was safe and clinically advantageous as a first-line HD regimen, offering faster neurological recovery, disability reversal, and minimal adverse event. These findings support incorporating neurological parameters of skin sensory changes, as lesion count alone does not appear to be a reliable marker of the clinical and neurological severity.

Indexed as

Hansen’s diseaseleprosymultidrug therapyRIMOXCLAMINtactile sensitivitytreatment

Identifiers

PMID42325645
PMCPMC13280636

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.